Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

@article{Fukuoka2011BiomarkerAA,
  title={Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).},
  author={Masahiro Fukuoka and Yi-Long Wu and Sumitra Thongprasert and Patrapim Sunpaweravong and S Y Leong and Virote R Sriuranpong and T Ivo Chao and Kazuhiko Nakagawa and Da-tong Chu and Nagahiro George Saijo and Emma L Duffield and Yuri Rukazenkov and Georgina Speake and Haiyi Jiang and Alison A Armour and Ka-fai To and James C Yang and Tony Shu Kam Mok},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 21},
  pages={2866-74}
}
PURPOSE The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status. PATIENTS AND METHODS In all, 1,217 patients were randomly assigned. Biomarkers analyzed were EGFR mutation (amplification mutation… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS